Enteric Disease Testing Market Size to Surpass USD 8.09 Billion by 2035 Driven by Technological Advancements and Rising Global Health Concerns

According to Precedence Research, the global enteric disease testing market size is projected to surpass USD 8.09 billion by 2035, increasing from USD 4.30 billion in 2025, expanding at a robust CAGR of 6.52%. Key factors fueling this expansion include the rising prevalence of gastrointestinal infections, particularly in developing regions, and rapid advancements in diagnostic technologies.

The market is becoming a critical component in the global healthcare infrastructure, offering solutions for the detection and treatment of bacterial, viral, and parasitic diseases that cause gastrointestinal distress.

The Complete Market Intelligence Report is Available Now 📥 Get Instant Access to Sample Pages 👉 https://www.precedenceresearch.com/sample/8259

The Role of AI in Enteric Disease Testing

Artificial intelligence (AI) is increasingly playing a transformative role in the enteric disease testing market. By automating sample analysis and enhancing accuracy, AI accelerates diagnosis, particularly for parasitic infections. AI algorithms also help manage large datasets, such as hospital records and geographic data, to predict infection trends and outbreaks, offering greater epidemiological insights.

🔗 Power Your Strategy with Full Market Data 👉 https://www.precedenceresearch.com/enteric-disease-testing-market

Enteric Disease Testing Market Key Growth Drivers

🔹 Increasing Prevalence of Gastrointestinal Infections: Rising bacterial, viral, and parasitic infections globally, especially in developing regions, are driving demand for rapid, accurate diagnostics.

🔹 Technological Advancements: The adoption of molecular diagnostics, AI integration, and rapid immunoassays are making testing more efficient and accurate.

🔹 Government Initiatives: Governments across regions are investing in improving healthcare infrastructure, especially in underserved areas, to ensure greater access to enteric disease testing.

➡️ Become a valued research partner with us https://www.precedenceresearch.com/schedule-meeting

Enteric Disease Testing Market Opportunities

🔹 CRISPR-Based Diagnostics: Technologies like SHERLOCK and DETECTR are expected to revolutionize the market by offering highly sensitive, rapid diagnostics at a lower cost.

🔹 Expanding Healthcare Markets in Emerging Economies: Growing healthcare access in regions like Asia-Pacific presents ample opportunities for market growth.

Enteric Disease Testing Market Trends

The enteric disease testing market is witnessing transformative shifts, particularly with the integration of cutting-edge technologies. Molecular diagnostics, including PCR and next-generation sequencing (NGS), are now dominating the space due to their high accuracy and fast turnaround times. These advancements are enabling more precise detection of pathogens in stool samples, a critical component of diagnosing diseases like Salmonella, E. coli, and Cryptosporidium.

In addition, artificial intelligence (AI) is playing a pivotal role in enhancing testing capabilities. By analyzing stool samples and large epidemiological datasets, AI is significantly improving diagnostic accuracy and speed. New product launches, the expansion of diagnostic laboratories, and strategic partnerships are accelerating the adoption of these innovative solutions, further solidifying the market's growth trajectory.

🔓 Instant Access. Zero Waiting. 📥 Buy the Premium Market Research Report Now 👉
https://www.precedenceresearch.com/checkout/8259

Enteric Disease Testing Market Regional Analysis

North America held a 38.5% market share in 2025, driven by strong regulatory frameworks, advanced healthcare infrastructure, and high adoption of molecular diagnostics. The presence of key industry players and continuous innovation further support regional growth. The U.S. leads the regional market due to technological advancements and increasing prevalence of infectious diseases. Strong research capabilities and widespread adoption of advanced diagnostic solutions contribute to market expansion.

Asia Pacific accounted for 24.5% of the market in 2025 and is expected to grow the fastest. Rising disease prevalence, increasing healthcare investments, and supportive government initiatives are driving regional expansion. China is a key contributor to regional growth due to increasing viral infections and expansion of private laboratories. Technological advancements and strong manufacturing capabilities further enhance market development.

Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.
📥 Download Sample Pages of the Report 👉 https://www.precedenceresearch.com/sample/8259

Enteric Disease Testing Market Segment Analysis

🔸 Disease Analysis

The bacterial enteric disease segment led the market with a 55.1% share in 2025 and is expected to grow further by 2035. This dominance is driven by the high prevalence of infections caused by Salmonella, E. coli, and Shigella, particularly in developing regions with inadequate sanitation. The rising incidence of foodborne and waterborne diseases continues to boost demand for accurate and rapid diagnostic testing.

The viral segment accounted for 28.4% of the market in 2025 and is projected to grow at the fastest rate. Increasing cases of rotavirus, norovirus, and adenovirus infections-especially among children are fueling demand for advanced molecular diagnostic solutions. Hospitals are prioritizing early detection to enable timely treatment and control outbreaks.

The parasitic segment held 16.5% market share in 2025, supported by the growing burden of infections such as Giardia, Entamoeba histolytica, and Cryptosporidium. These diseases are prevalent in tropical regions with limited access to clean water, driving the use of specialized diagnostic techniques like antigen-based assays and microscopy.

🔸 Technology Analysis

Molecular diagnostics dominated the market with a 45% share in 2025 due to its high sensitivity, accuracy, and faster turnaround time. Technologies like PCR enable simultaneous detection of multiple pathogens from a single sample, making them highly preferred in hospital laboratories.

Immunoassays accounted for 30% of the market in 2025, driven by their affordability and rapid results. Techniques such as ELISA and lateral flow assays are widely used in point-of-care settings, particularly for detecting bacterial antigens.

Traditional culture methods held a 25% share and remain important for pathogen identification and antimicrobial susceptibility testing. Their cost-effectiveness and regulatory acceptance continue to support adoption in diagnostic laboratories.

Advanced technologies like chromatography and spectrometry are gaining traction due to their high precision and ability to detect toxins and biomarkers. Innovations in gas and liquid chromatography are enhancing diagnostic accuracy.

🔸 Product & Service Analysis

Reagents and consumables represented the largest market share in 2025, as they are essential for conducting diagnostic tests. Their widespread use in molecular diagnostics and sample analysis drives consistent demand, supported by ongoing innovations in assay kits and reagents.

The instruments segment holds a significant share due to increasing adoption of automated systems such as PCR analyzers and immunoassay platforms, which improve laboratory efficiency and accuracy.

Software and services are gaining importance with the growing need for data management and analytics. These solutions enable real-time tracking, improved decision-making, and seamless integration with diagnostic systems.

🔸 End-User Analysis

Hospital laboratories dominated the market in 2025 due to their advanced infrastructure and ability to deliver rapid diagnostic results. Increased patient preference and investment in modern lab facilities are driving this segment. Pharmaceutical and biotechnology companies are expected to witness strong growth, supported by increasing investments in research, drug development, and clinical trials related to infectious diseases.

Diagnostic centers are expanding rapidly, particularly in urban areas, and are adopting advanced equipment to enhance testing capabilities, contributing to market growth. These institutes play a vital role in innovation and rely heavily on advanced diagnostic technologies for research, clinical validation, and development of new treatment methods.

Enteric Disease Testing Market Companies and Their Offerings

➢ Abbott Laboratories: Immunoassays and molecular tests (e.g., Alinity m system) for infectious diseases including gastrointestinal pathogens; part of broader infectious disease menu.

➢ Becton, Dickinson and Company (BD): BD MAX Enteric Viral Panel (FDA-cleared molecular test for viral gastroenteritis pathogens); complete portfolio for bacterial, viral, and parasitic GI infections.

➢ bioMérieux SA: VIDAS automated serological tests on stool samples; CHROMID culture media for Salmonella, Campylobacter, Vibrio, and C. difficile; syndromic PCR panels via FILMARRAY for GI pathogens.

➢ Danaher Corporation (Cepheid): GeneXpert systems and Xpert molecular diagnostics; broad portfolio including tests for enteric-related infections like TB and emerging pathogens, adaptable for GI panels.

➢ Thermo Fisher Scientific Inc.: Molecular and immunoassay solutions for pathogen detection in enteric diseases (specific GI panels noted in market involvement).

➢ Bio-Rad Laboratories, Inc.: Immunoassays and diagnostics for bacterial/viral enteric pathogens; active in enteric testing market.

➢ Roche Holding AG: Molecular diagnostics platforms (e.g., cobas systems) for infectious diseases; supports GI pathogen testing via PCR assays.

➢ Hologic, Inc.: Diagnostic platforms like Panther system for molecular testing; covers infectious diseases including potential enteric applications.

➢ QuidelOrtho Corporation: Rapid molecular and immunoassay tests for infections; syndromic panels adaptable for GI pathogens.

➢ PerkinElmer, Inc.: Molecular diagnostics for infectious diseases; supports high-throughput enteric pathogen screening.

➢ Neogen Corporation: Testing solutions for foodborne pathogens (e.g., bacterial enteric risks like Salmonella); lab services for enteric detection.

➢ SGS SA: Laboratory testing services for enteric pathogens in food, water, and clinical samples.

➢ QIAGEN N.V.: PCR-based kits and automation for detecting enteric viruses/bacteria (e.g., norovirus, rotavirus).

➢ DiaSorin S.p.A: Molecular and immunoassay tests for GI infections; listed in market reports for enteric panels.

➢ Meridian Bioscience, Inc: Immunoassays and molecular tests for enteric pathogens like C. difficile, norovirus, and rotavirus.

Latest Industry Developments:

🔸 Roche launched the Cobas MPX-E assay in March 2026, designed to improve pathogen detection in diagnostic centers.

🔸 Hologic, Inc. received FDA approval in October 2025 for their expanded gastrointestinal (GI) bacterial assays.

🔸 Bio-Rad Laboratories launched the EZ-Check Salmonella spp. Kit in August 2025, advancing the detection of salmonellosis.

Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.
🔓 Instant Delivery Available | 💎 Buy Premium Report 👉 https://www.precedenceresearch.com/checkout/8259

Segments Covered in the Report

🔹 By Disease Type

Bacterial Enteric Disease (C. Difficile, Salmonella, E. Coli, Campylobacter, H. Pylori, Cholera, Shigella)
Viral Enteric Disease (Norovirus, Rotavirus, Adenovirus)
Parasitic Enteric Disease (Amebiasis, Cryptosporidiosis, Giardiasis)

🔹 By Technology

Molecular Diagnostics (PCR, NAAT, NGS)
Immunoassays (ELISA, Rapid Antigen Tests)
Traditional Culture Methods
Chromatography & Spectrometry

🔹 By Product & Service

Reagents & Consumables
Instruments/Equipment
Software & Services

🔹 By End-User

Hospital Laboratories
Diagnostic Centers
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

🔹 By Region

North America
Latin America
Europe
Asia-pacific
Middle and East Africa

Connect With Us

📞 USA: +1 804 441 9344
📞 APAC: +61 485 981 310 or +91 87933 22019 | +6531051271
📞 Europe: +44 7383 092 044
📩 Email: sales@precedenceresearch.com

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

🌐 Web: https://www.precedenceresearch.com

Our Trusted Data Partners:
🔹https://www.towardshealthcare.com
🔹https://www.towardspackaging.com
🔹https://www.towardschemandmaterials.com
🔹https://www.towardsfnb.com
🔹https://www.marketstatsinsight.com

Get Recent News:
https://www.precedenceresearch.com/news

For the Latest Update, Follow Us:
🔹https://www.linkedin.com/company/precedence-research
🔹https://x.com/Precedence_R
🔹https://www.facebook.com/precedenceresearch
🔹https://precedence-research.medium.com/

This release was published on openPR.